EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells

被引：0
|
作者：
Katayama, Yuki [1 ]
Yamada, Tadaaki [1 ]
Tanimura, Keiko [1 ]
Morimoto, Kenji [1 ]
Yoneda, Kazue [2 ]
Horinaka, Mano [3 ]
Sakai, Toshiyuki [3 ]
Ozasa, Hiroaki [4 ]
Takayama, Koichi [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Dept Pulm Med, Grad Sch Med Sci, Kyoto, Japan
[2] Hyogo Coll Med, Dept Omics Med, Nishinomiya, Hyogo, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Drug Discovery Med, Kyoto, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO38-3
引用
收藏
页码：S1421 / S1421
页数：1
相关论文
共 50 条
  • [21] Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers
    Yoshida, Ryohei
    Okumura, Shunsuke
    Sasaki, Takaaki
    Osaki, Yoshinobu
    CANCER RESEARCH, 2016, 76
  • [22] Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer
    Recondo, Gonzalo
    Mezquita, Laura
    Planchard, David
    Gazzah, Anas
    Facchinetti, Francesco
    Bigot, Ludovic
    Rizvi, Ahsan Z.
    Thiery, Jean-Paul
    Scoazec, Jean-Yves
    Frias, Rosa L.
    Sourisseau, Tony
    Mahjoubi, Linda
    Galissant, Justine
    Abou-Lovergne, Aurelie
    Vassal, Gilles
    Bahleda, Rastislav
    Hollebecque, Antoine
    Nicotra, Claudio
    Ngocamus, Maud
    Michiels, Stefan
    Lacroix, Ludovic
    Richon, Catherine
    Auger, Nathalie
    De Baere, Thierry
    Deschamps, Frederic
    Salary, Eric
    Olaussen, Ken A.
    Angevin, Eric
    Eggermont, Alexander
    Andre, Fabrice
    Massard, Christophe
    Soria, Jean-Charles
    Besse, Benjamin
    Friboulet, Luc
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients
    Clave, S.
    Salido, M.
    Gibert, J.
    Hardy-Werbin, M.
    Weingartner, E.
    Hernandez, J.
    Nichol, D.
    Rocha, P.
    Riera, X.
    Blanco, R.
    Bosch-Barrera, J.
    Taus, A.
    Pijuan, L.
    Bellosillo, B.
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S508 - S509
  • [24] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [25] Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Numata, Takeshi
    Endo, Takeo
    Yamamoto, Yusuke
    Shimizu, Kei
    Yamada, Hideyasu
    Hayashihara, Kenji
    Okauchi, Shinichiro
    Satoh, Hiroaki
    Yamada, Yutaka
    Tamura, Tomohiro
    Saito, Kazuto
    Kikuchi, Norihiro
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Watanabe, Hiroko
    Shiozawa, Toshihiro
    Hizawa, Nobuyuki
    Funayama, Yasunori
    Hayashi, Shigen
    Nakamura, Hiroyuki
    Yamashita, Takaaki
    IN VIVO, 2020, 34 (04): : 2001 - 2007
  • [26] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [27] Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
    Awad, Mark
    Mastini, Cristina
    Patino, Rafael
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy
    Adeni, Anika
    Lydon, Christine
    Janne, Pasi
    Chiarle, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1163
  • [28] GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
    Yuki Shimizu
    Koutaroh Okada
    Jun Adachi
    Yuichi Abe
    Ryohei Narumi
    Ken Uchibori
    Noriko Yanagitani
    Sumie Koike
    Satoshi Takagi
    Makoto Nishio
    Naoya Fujita
    Ryohei Katayama
    npj Precision Oncology, 6
  • [29] Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
    Blasco, Rafael B.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [30] GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
    Shimizu, Yuki
    Okada, Koutaroh
    Adachi, Jun
    Abe, Yuichi
    Narumi, Ryohei
    Uchibori, Ken
    Yanagitani, Noriko
    Koike, Sumie
    Takagi, Satoshi
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
12345